RegeneRx Biopharmaceuticals (RGRX) Stock Statistics & Valuation Metrics

RegeneRx Biopharmaceuticals has a market cap or net worth of $1.05K. The enterprise value is $1.16M.

RegeneRx Biopharmaceuticals has 1,496,966 shares outstanding. The number of shares has decreased by -2.65% in one year.

RegeneRx Biopharmaceuticals’s return on equity (ROE) is 0.50 and return on invested capital (ROIC) is 1654.75%.

The current PE Ratio of RegeneRx Biopharmaceuticals is ―. RegeneRx Biopharmaceuticals’s PEG ratio is -0.16.

In the last 12 months, RegeneRx Biopharmaceuticals had revenue of 76.76K and earned -1.73M in profits. Earnings per share was -1.00.

In the last 12 months, operating cash flow was -823.75K and capital expenditures 0.00, giving a free cash flow of -823.75K billion.

RegeneRx Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

RegeneRx Biopharmaceuticals upcoming earnings date is May 15, 2018, After Close (Confirmed).

RegeneRx Biopharmaceuticals as a current ratio of 0.55, with Debt / Equity ratio of -41.98%

In the past 12 months, RegeneRx Biopharmaceuticals has paid 0.00 in taxes.

RegeneRx Biopharmaceuticals EV to EBITDA ratio is -1.42K, with an EV/FCF ratio of -2.12K.

RegeneRx Biopharmaceuticals has $101.56K in cash and marketable securities with $1.49M in debt, giving a net cash position of -$1.39M billion.

Gross margin is 100.00%, with operating margin of -1826.45%, and net profit margin of -2249.84%.

The average price target for RegeneRx Biopharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―